All In Biotech

NDA 021817 · Sandoz

Reclast

Zoledronic Acid · Intravenous

Priority review

Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Apr 16, 2007

Approved uses

5

Original approval plus efficacy supplements

Registered trials

363

118 Phase 3, 24 recruiting

FAERS reports

40,714

35,240 serious, 5,181 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 3, 2026.

Reclast is a bisphosphonate indicated for: • Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) • Treatment to increase bone mass in men with osteoporosis ( 1.3 ) • Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) • Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women Reclast is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Reclast reduces the incidence of fractures (hip, vertebral, and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, Reclast reduces the incidence of new clinical fractures [see Clinical Studies ( 14.1 )]. 1.2 Prevention of Osteoporosis in Postmenopausal Women Reclast is indicated for prevention of osteoporosis in postmenopausal women [see Clinical Studies ( 14.2 )]. 1.3 Osteoporosis in Men Reclast is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies ( 14.3 )]. 1.4 Glucocorticoid-Induced Osteoporosis Reclast is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months [see Clinical Studies ( 14.4 )]. 1.5 Paget's Disease of Bone Reclast is indicated for treatment of Paget's disease of bone...

Mechanism: Reclast is a bisphosphonate and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered zoledronic acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover. The main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. The relatively long duration of action of zoledronic acid is attributable to its high binding affinity to bone mineral.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RECLAST · ZOLEDRONIC ACID EQ 5MG BASE/100ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Zoledronic Acid" as an intervention, any sponsor and status, largest first.

All 363 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • arthralgia3,285
  • pain3,218
  • fatigue2,877
  • nausea2,875
  • pyrexia2,875
  • osteonecrosis of jaw2,775
  • death2,522
  • headache2,431
  • diarrhoea2,335
  • vomiting2,090
  • asthenia2,015
  • myalgia1,908

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200440
200592
2006108
2007281
2008853
20091,339
20101,535
20112,241
20122,416
2013996
2014809
20151,331
20161,465
20171,673
20182,318
20192,676
20202,708
20212,705
20222,796
20233,043
20243,317
20253,556
20262,415

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Reclast (Zoledronic Acid/Mannitol-Water)

2024 spending

$106K

Beneficiaries

104

105 claims

Per beneficiary

$1,015

$10.05 per unit

View as table
YearSpending
2020$71,172
2021$84,934
2022$55,662
2023$85,278
2024$105,537

Part B: Reclast* (Zoledronic Acid/Mannitol-Water*) · HCPCS J3489

2024 spending

$4.2M

Beneficiaries

96,550

143,810 claims

Per beneficiary

$43

2024 ASP limit $6.59 per unit

View as table
YearSpending
2020$6,211,801
2021$6,038,889
2022$4,257,950
2023$5,306,181
2024$4,175,001

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 740 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.